Nanopublications

@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix ns1: <http://www.w3.org/ns/prov#> .
@prefix this: <http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ> .
@prefix sub: <http://purl.org/np/RA8UPrR6-PGx67LPiKT1aH-uqWY7vucrWs4m8-2693LfQ#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_7148> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_7148> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB00073> ;
    a rdf:Statement ;
    rdfs:label "rituxan rituximab is a cd2 directed cytolytic antibody indicated for the treatment of adult patients with non hodgkin s lymphoma nhl 1 1 relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine and prednisone chop or other anthracycline based chemotherapy regimens chronic lymphocytic leukemia cll 1 2 previously untreated and previously treated cd2 positive cll in combination with fludarabine and cyclophosphamide fc rheumatoid arthritis ra in combination with methotrexate in adult patients with moderately to severely active ra who have inadequate response to one or more tnf antagonist therapies 1 3 granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa in adult patients in combination with glucocorticoids 1 4 moderate to severe pemphigus vulgaris pv in adult patients 1 5 rituxan rituximab is indicated for the treatment of adult patients with relapsed or refractory low grade or follicular cd2 positive b cell nhl as a single agent previously untreated follicular cd2 positive b cell nhl in combination with first line chemotherapy and in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy as single agent maintenance therapy non progressing including stable disease low grade cd2 positive b cell nhl as a single agent after first line cyclophosphamide vincristine and prednisone cvp chemotherapy previously untreated diffuse large b cell cd2 positive nhl in combination with cyclophosphamide doxorubicin vincristine prednisone chop or other anthracycline based chemotherapy regimens rituxan is indicated in combination with fludarabine and cyclophosphamide fc for the treatment of adult patients with previously untreated and previously treated cd2 positive cll rituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tnf antagonist therapies rituxan in combination with glucocorticoids is indicated for the treatment of adult patients with granulomatosis with polyangiitis gpa wegener s granulomatosis and microscopic polyangiitis mpa rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB00073> bl:category bl:Drug .
}

sub:provenance {
sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "YDcxNp4yFb+jd0h70HCt+BBkb4ZchN6ne3J1nCFc4paXBPzEulsalYXCO2GKx+GD6yKlnfFaR3SgWkKm7bfKlYk0SCDkrFxGL1eWvy6a6s500M3YS11pJaOSzKNqhCOdRku30grMgz7kGWG8RlHTmvxP6PWFS90sYDb4y1iHvu0=" ;
    npx:hasSignatureTarget this: .
  this: dcterms:created "2021-07-03T15:24:17.881+02:00"^^xsd:dateTime ;
    dcterms:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}